Head-to-head · WeighScore
Hims & Hers vs Oria Meds
The verdict
Hims & Hers takes it — 75.6/100 to 63.6/100.
Hims & Hers grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mass-market app-first program with nationwide reach and consumer-grade polish.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Hims & Hers | Oria Meds |
|---|---|---|
| WeighScore | 75.6/100 | 63.6/100 |
| Grade | C | C |
| Scorecard rank | #55 | #268 |
| Semaglutide | $199/mo | $199/mo (first month $89; the three- and six-month plans both cost $209 a month) |
| Tirzepatide | Not disclosed | $369/mo (first month $129; three months $316/mo, six months $299/mo) |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #55 · C
FDAWarning letter issued to Hims & Hers Health, Inc. dba Hims in September 2025. See the FDA warning-letter database.
Strengths
- Nationwide
- Polished app
- Strong brand trust
Where it loses points
- Tirzepatide pricing inconsistently disclosed
- Industry-wide compounding scrutiny
Graded #268 · C
Strengths
- Names its dispensing pharmacy, PerfectRx, with a street address and a phone number
- Free shipping and interest-free installments are offered at checkout
- The intake's plan menu returned identical ladders in two different states, so the price is not being varied by geography in the states tested
- Coverage is stated as all 50 states, subject to provider availability
Where it loses points
- Neither semaglutide nor tirzepatide is named anywhere on the public site; the molecule first appears at step two of the intake, after name, email, phone and shipping address are collected
- The homepage sells “starting at $149” and “starting at $249” and neither figure appears in the intake in either state tested
- The semaglutide ladder is inverted: one month is $199 a month, three months and six months are both $209 a month
- $89 and $129 are first-month promotional rates; the standing rates are $199 and $369
- A second price table sits in the homepage script and renders nowhere, quoting a $329 tirzepatide figure the live intake contradicts
- Two different scarcity counters appear on consecutive checkout screens, and review turnaround is stated as 24 hours in one place and 48 in another
- No legal entity, state of organization or governing law is published, and no clinician or NPI is named
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 536 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.